A TARGETED APPROACH TO ACTIVATE CELLULAR CLEARANCE Caraway’s therapeutic approach leverages genetic data and unique biological understanding to develop proprietary small molecules that activate cellular clearance and recycling processes – accelerating clearance of accumulated toxic materials and defective cellular components. New insights in genetics highlight the link between lysosomal function and pathologies in multiple organ systems, including the central nervous system (CNS), heart, kidney, and muscle. Caraway is a leader in targeting these mechanisms with potentially disease-modifying compounds for patients suffering the devastating effects of neurodegenerative and rare diseases including Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and lysosomal storage diseases (LSDs).
View Top Employees from Caraway Therapeutics, Inc.Website | http://carawaytx.com/ |
Revenue | $4 million |
Employees | 22 (22 on RocketReach) |
Founded | 2018 |
Address | 300 Technology Square Suite 201, Cambridge, Massachusetts 02139, US |
Phone | (617) 245-8188 |
Technologies |
JavaScript,
HTML,
PHP
+10 more
(view full list)
|
Industry | Biotechnology Research, Biotechnology, Drug Discovery, Pharmaceuticals, Drug Delivery, Healthcare |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 54171 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 541714 Companies |
Looking for a particular Caraway Therapeutics, Inc. employee's phone or email?
The Caraway Therapeutics, Inc. annual revenue was $4 million in 2024.
Martin Williams is the CEO of Caraway Therapeutics, Inc..
22 people are employed at Caraway Therapeutics, Inc..
Caraway Therapeutics, Inc. is based in Cambridge, Massachusetts.
The NAICS codes for Caraway Therapeutics, Inc. are [54171, 541, 54, 5417, 541714].
The SIC codes for Caraway Therapeutics, Inc. are [873, 87].